

NCT01909934 Raw comparison:

Summary:
CHIA has 13 criteria while your personal folder has 15 criteria
Total found criteria: 12/13
Total not Found: 1/13
Total Extra: 2
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male or female patients age 18 years or older with │ Male or female participants age 18 years or older  │
│ relapsed or refractory sALCL who have previously   │ with relapsed or refractory sALCL who have         │
│ received at least 1 multiagent chemotherapy        │ previously received at least 1 multiagent          │
│                                                    │ chemotherapy                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Bidimensional measurable disease                   │ Bidimensional measurable disease                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ An Eastern Cooperative Oncology Group (ECOG)       │ An Eastern Cooperative Oncology Group (ECOG)       │
│ performance status of 0 or 1                       │ performance status of 0 or 1                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female patients who are postmenopausal for at      │ Female participants who are postmenopausal for at  │
│ least 1 year before the screening visit surgically │ least 1 year before the screening visit surgically │
│ sterile or agree to practice 2 effective methods   │ sterile or agree to practice 2 effective methods   │
│ of contraception at the same time from the time of │ of contraception at the same time from the time of │
│ signing the informed consent form through 30 days  │ signing the informed consent form through 30 days  │
│ after the last dose of study drug or agree to      │ after the last dose of study drug or agree to      │
│ practice true abstinence                           │ practice true abstinence                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Male patients who agree to practice effective      │ Male participants who agree to practice effective  │
│ barrier contraception during the entire study      │ barrier contraception during the entire study      │
│ treatment period through 6 months after the last   │ treatment period through 6 months after the last   │
│ dose of study drug or agree to practice true       │ dose of study drug or agree to practice true       │
│ abstinence                                         │ abstinence                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinical laboratory values as specified in the     │ Clinical laboratory values as specified in the     │
│ study protocol                                     │ study protocol                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous treatment with brentuximab vedotin        │ Previous treatment with brentuximab vedotin        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previously received an allogeneic transplant       │ Previously received an allogeneic transplant       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known cerebral/meningeal disease including signs   │ Known cerebral/meningeal disease including signs   │
│ or symptoms of progressive multifocal              │ or symptoms of progressive multifocal              │
│ leukoencephalopathy (PML)                          │ leukoencephalopathy (PML)                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female patients who are lactating and              │ Female participants who are lactating and          │
│ breastfeeding or pregnant                          │ breastfeeding or pregnant                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known human immunodeficiency virus (HIV) positive  │ Known human immunodeficiency virus (HIV) positive  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known hepatitis B surface antigen-positive or      │ Known hepatitis B surface antigen-positive or      │
│ known or suspected active hepatitis C infection    │ known or suspected active hepatitis C infection    │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                               │
╞═══════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Patients with current diagnosis of primary cutaneous ALCL (patients whose ALCL has transformed to │
│ sALCL are eligible)                                                                               │
╘═══════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                          │
╞══════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Participants with current diagnosis of primary cutaneous anaplastic large cell lymphoma \[ALCL\] │
│ (participants whose ALCL has transformed to sALCL are eligible)                                  │
├──────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                │
╘══════════════════════════════════════════════════════════════════════════════════════════════════╛